What is Clex Bio?
Clex Bio is a Norway-based biotechnology firm focused on pioneering breakthrough solutions for tissue engineering and single-cell analysis. The company leverages advanced bio-fabrication techniques, integrating them with its unique hydrogel technology, CLEX. This innovative approach positions Clex Bio at the forefront of regenerative medicine and cellular research, offering advanced tools for scientific discovery and therapeutic development. The company's commitment to combining cutting-edge bio-fabrication with proprietary material science aims to address complex challenges in biological research and clinical applications.
How much funding has Clex Bio raised?
Clex Bio has raised a total of $2.2M across 1 funding round:
Angel/Seed
$2.2M
Angel/Seed (2021): $2.2M, investors not publicly disclosed
What's next for Clex Bio?
With the recent influx of major strategic investment, Clex Bio is poised for accelerated growth and innovation. The substantial capital infusion is expected to fuel the expansion of its research and development initiatives, enhance its bio-fabrication capabilities, and potentially broaden its market reach. This funding will likely support the scaling of its proprietary hydrogel technology and its application in advanced tissue engineering and single-cell techniques. Clex Bio's strategic direction will focus on solidifying its position as a leader in biotech solutions, driving forward its mission to revolutionize regenerative medicine and cellular research through technological advancement.
See full Clex Bio company page
